Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens
NCT ID: NCT01706770
Last Updated: 2020-10-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2012-05-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Clinical Performance of Two Monthly Replacement Toric Soft Contact Lenses
NCT06165627
Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens
NCT01094730
Clinical Evaluation of Daily Disposable Contact Lenses
NCT02097030
Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses
NCT04980456
Multi-Centre Clinical Evaluation of Two Reusable Soft Contact Lenses
NCT02815735
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
enfilcon A
The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
enfilcon A
galyfilcon A
The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
galyfilcon A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
enfilcon A
galyfilcon A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be at least 18 years of age as of the date of evaluation for the study.
* Have read the Informed Consent, been given an explanation of the Informed Consent, indicated understanding of the Informed Consent, signed the Informed Consent document.
* Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
* Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses in both eyes on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
* Possess wearable and visually functional eyeglasses.
* Be in good general health, based on his/her knowledge.
* Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 2.00 diopters of refractive astigmatism and be willing to wear contact lenses in both eyes.
* Have: manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
* Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.
To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.
Exclusion Criteria
* Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
* Poor personal hygiene.
* Any active participation in another clinical trial within 30 days prior to this study.
* Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the study period.
* A member, relative or household member of the investigator or of the investigational office staff.
* Has a known sensitivity to ingredients used in the care products approved for use in the study.
* Previous refractive surgery; or current or previous orthokeratology treatment.
* Is aphakic or psuedophakic.
* Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
* The need for topical ocular medications or any medication which might interfere with contact lens wear or which would require the lenses to be removed during the day.
* The presence of clinically significant (grade 3 or 4) anterior segment abnormalities.
* Any; inflammations such as iritis; or any infection or allergic reaction of the eye, lids, or associated structures.
* A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.
* A history of papillary conjunctivitis that has interfered with contact lens wear.
* Slit lamp findings that would contraindicate contact lens wear, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2, Pterygium, Corneal scars within the visual axis, Neovascularization or ghost vessels \> 1.0 mm in from the limbus, Giant papillary conjunctivitis (GPC) of \> Grade 1, Anterior uveitis or iritis, Seborrheic eczema, seborrheic conjunctivitis or blepharitis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott E Schachter, OD
Role: PRINCIPAL_INVESTIGATOR
Unafiliated
Cheryl Vincent-Reimer, OD
Role: PRINCIPAL_INVESTIGATOR
Unafiliated
Eric White, OD
Role: PRINCIPAL_INVESTIGATOR
Unafiliated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Eyecare
Pismo Beach, California, United States
Eric M. White, OD, Inc.
San Diego, California, United States
Vision Care Associates
East Lansing, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FC111216
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.